Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Comparison of Physiologic Response With Rate Adaptive Pacing Driven by Minute Ventilation and Accelerometer (RAP)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02003378
Recruitment Status : Unknown
Verified December 2013 by Sujata S. Balulad, MD, Albany Medical College.
Recruitment status was:  Recruiting
First Posted : December 6, 2013
Last Update Posted : December 6, 2013
Sponsor:
Collaborator:
Boston Scientific Corporation
Information provided by (Responsible Party):
Sujata S. Balulad, MD, Albany Medical College

Brief Summary:
Some patients' heart rates do not increase as needed during activities and exercise, which can make them feel tired and fatigued easily. The patients in this study have a pacemaker with a FDA approved rate response sensor, which senses activity level by sensing motion (through a component known as an accelerometer) and/or breathing changes (known as minute ventilation). These changes in motion or breathing make the pacemaker increase the patient's heart rate. This study is being conducted to see which rate response sensor is better (motion driven or breathing driven). The study is also investigating whether optimizing the sensor based on the individual patient will give better results in terms of increasing the patient's exercise capacity. The hypothesis is that rate responsive pacing driven by the minute ventilation sensor results in improved functional capacity compared to accelerometer in chronotropically incompetent patients.

Condition or disease Intervention/treatment Phase
Chronotropic Incompetence Device: Pacemaker sensor set to MV Device: Pacemaker sensor set to XL Not Applicable

Detailed Description:

This study is a double-blind, randomized, two-arm (with crossover to other arm) trial that will investigate the benefit of rate responsive pacing with either MV or XL in pacemaker patients that have chronotropic incompetence (CI). Blinding will occur for both the patient and the research personnel who are collecting primary endpoint data. The study will enroll patients that have an implanted dual/single chamber pacemaker, which has both the minute ventilation (MV) and accelerometer (XL) rate-adaptive sensors.

The initial study visit called as baseline visit for newly implanted patients (at 2 weeks from implant) and for previously implanted patients (at the time of enrolling in the study).

Patients will complete a 6-min walk test at the baseline study visit to screen for CI based on the intrinsic heart rate achieved during the walk while pacemaker set to DDD/VVI with both sensors set to passive. All patients that are enrolled in the study will get treadmill exercise stress test by chronotropic assessment exercise protocol (CAEP) to confirm CI. Patients will be determined to have CI by completing a maximal effort exercise treadmill stress test with peak perceived exertion by Borg scale of >16 (18) with the pacemaker programmed to DDD/VVI with both device sensors set to passive. Patients that do not meet the criteria of CI after CAEP treadmill test will not continue in the trial.

Patients that have CI will then be randomized in a 1:1 ratio to programming the rate-adaptive sensor to either MV or XL. The MV or XL rate-adaptive sensor will be optimized for each patient using stress test derived age predicted maximum heart rate by adjusting response factor to achieve MCR slope of 1.

At the 4-week visit, patients that have CI will complete a second CAEP treadmill test in their randomized setting with pacer set as DDDR/VVIR. They will also complete 6-minute walk test and pacemaker interrogation. They will be crossed over to the other sensor group at this time by changing the sensor setting.

At 8 week visit, patients will have another CAEP treadmill test, 6-minute walk test and pacemaker interrogation in their randomized crossed over group setting.

Patients that have CI will get quality of life assessment using SF-36 questionnaire and Aquarel questionnaire at baseline visit, 4 and 8 week visit in their randomized setting.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Comparison of Physiologic Response With Rate Adaptive Pacing Driven by Minute Ventilation and Accelerometer
Study Start Date : September 2013
Estimated Primary Completion Date : June 2014
Estimated Study Completion Date : June 2014

Arm Intervention/treatment
Active Comparator: Minute Ventilation (MV)
Pacemaker sensor set to MV (Cross over study)
Device: Pacemaker sensor set to MV
Pacemaker sensor set to minute ventilation

Active Comparator: Accelerometer (XL)
Pacemaker sensor set to XL (Cross over study)
Device: Pacemaker sensor set to XL
Pacemaker sensor set to accelerometer




Primary Outcome Measures :
  1. Metabolic chronotropic relationship (MCR) slope [ Time Frame: 2 weeks, 6 weeks, and 10 weeks post-implant/post enrollment ]
    Improvement in functional capacity, determined by MCR slope - if greater using the minute ventilation senor of the accelerometer sensor in patients with chronotropic incompetence


Secondary Outcome Measures :
  1. Changes in heart rate and distance covered during 6-minute walk test [ Time Frame: 2 weeks, 6 and 10 weeks post-implant/post enrollment ]
    To evaluate the superiority of the minute ventilation sensor or the accelerometer sensor by comparing changes in heart rate and distance covered during activities using a 6 minute walk test.

  2. Exercise time during chronotropic assessment exercise protocol (CAEP) stress test [ Time Frame: 2 weeks, 6 and 10 weeks post-implant/post enrollment ]
    To evaluate the superiority of the minute ventilation sensor or the accelerometer sensor related to exercise time during the CAEP stress test

  3. Quality of life (QOL) assessment [ Time Frame: 2 weeks, 6 and 10 weeks post-implant/post enrollment ]
    SF-36 questionnaire and Aquarel questionnaire to assess quality of life



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Willing and capable of providing informed consent for participation
  • Previously received, or previously scheduled to receive, dual-chamber/single chamber pacemaker with active atrial and ventricular leads.Boston Scientific Ingenio K172, K173, K174; or (both Ingenio and Advantio have similar rate response features) Advantio K062, K063, K064 (Boston Scientific CRM, St. Paul, MN).
  • Plans to remain in the long-term care of his/her enrolling physician and is available for study follow-up for three months post-enrollment
  • Patients with or without one or more of the following are permitted to enroll:
  • Sinus node dysfunction with pacemaker
  • Mobitz II second degree heart block or third degree heart block with pacemaker
  • Chronic atrial fibrillation and other atrial arrhythmias with controlled heart rate within the past 90 days prior to consent
  • Paroxysmal atrial fibrillation on rate controlling medication as long as same rhythm stays throughout the study, sinus or atrial fibrillation.
  • Patients with pacemakers requiring beta blocker (or other rate limiting medications) therapy

Exclusion Criteria:

  • Neuromuscular, orthopedic, or vascular disability that prevents normal walking (e.g., intermittent claudication, arthritis, residual stroke weakness, need for a wheelchair or walker)
  • A symptom-limited exercise protocol is thought to be dangerous or contra-indicated, including but not limited to changing pattern of chest discomfort, unstable angina or uncontrolled arrhythmias Severe pulmonary disease with inability to exercise
  • Severe heart failure with dyspnea at rest and inability to exercise (NYHA class IV) and qualify for the CRT-D
  • Life expectancy is less than 12 months due to other medical conditions, per physician discretion
  • Has or indicated for an implantable cardioverter defibrillator (ICD) or cardiac resynchronization therapy-defibrillator (CRT-D)
  • Currently, or within 30 days prior to consent, enrolled in another investigational study that would directly impact the treatment or outcome of the current study.
  • Younger than 18 years of age
  • Patients with pacemakers of unipolar atrial or ventricular lead configuration
  • Patients with abdominal pacemaker implants
  • Patients on a ventilator
  • Patients with a pacemaker with epicardial lead
  • Patients with Pneumothorax, pericardial effusion or pleural effusion
  • Pregnant or planning to become pregnant during the study (method of assessment upon physician's discretion). Pregnancy test will be done for all female patients of childbearing age before the study, and at each visit.
  • Unable or unwilling to comply with the protocol requirements

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02003378


Contacts
Layout table for location contacts
Contact: Wendy Stewart, MS 518-262-9316 stewarw@mail.amc.edu
Contact: Sujata Balulad, MD 518-262-5076 balulas@mail.amc.edu

Locations
Layout table for location information
United States, New York
Albany Medical College Recruiting
Albany, New York, United States, 12208
Contact: Wendy Stewart, MS    518-262-9316    stewarw@mail.amc.edu   
Principal Investigator: Sujata Balulad, MD         
Sub-Investigator: Henry Tan, MD         
Sub-Investigator: Steven Fein, MD         
Sponsors and Collaborators
Albany Medical College
Boston Scientific Corporation
Investigators
Layout table for investigator information
Principal Investigator: Sujata Balulad, MD Albany Medical College
Layout table for additonal information
Responsible Party: Sujata S. Balulad, MD, Principal Investigator, Albany Medical College
ClinicalTrials.gov Identifier: NCT02003378    
Other Study ID Numbers: RAP
First Posted: December 6, 2013    Key Record Dates
Last Update Posted: December 6, 2013
Last Verified: December 2013
Keywords provided by Sujata S. Balulad, MD, Albany Medical College:
Chronotropic incompetence